{
    "clinical_study": {
        "@rank": "18447", 
        "arm_group": [
            {
                "arm_group_label": "ITI-007", 
                "arm_group_type": "Experimental", 
                "description": "Part 1: Healthy geriatric volunteers with multiple oral dose escalation up to and including 20 mg ITI-007\nPart 2: Geriatric patients with dementia with ITI-007 given"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Part 1: Healthy geriatric volunteers with placebo given\nPart 2: Geriatric patients with dementia with placebo given"
            }
        ], 
        "brief_summary": {
            "textblock": "A Phase 1b/2, Randomized, Double-blind, Placebo-Controlled, Multiple Oral Dose Escalation\n      Study to Assess Safety, Tolerability and Pharmacokinetics of ITI-007 in Healthy Geriatric\n      Volunteers and in Geriatric Patients with Dementia"
        }, 
        "brief_title": "Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Alzheimer's Disease", 
        "condition_browse": {
            "mesh_term": [
                "Alzheimer Disease", 
                "Dementia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Part 1\n\n          -  Healthy geriatric volunteers\n\n          -  MMSE score of >= 26 at screening\n\n          -  BMI between 19.0 and 40.0 kg/m2 and a minimum body weight of 50 kg at screening\n\n        Part 2\n\n          -  Geriatric patients with a clinical diagnosis of dementia\n\n          -  MMSE score of < 26 at screening\n\n          -  BMI between 19.0 and 40.0 kg/m2 and a minimum body weight of 50 kg at screening\n\n        Exclusion Criteria:\n\n          -  Any clinically significant illness within 6 months before screening\n\n          -  Any history of cancer within last 5 years\n\n          -  History of Hepatitis B or C infection and elevated ALT, AST or bilirubin above the\n             upper limit of normal level\n\n          -  Any subject considered to be an imminent danger to themselves or others"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02078310", 
            "org_study_id": "ITI-007-200"
        }, 
        "intervention": [
            {
                "arm_group_label": "ITI-007", 
                "intervention_name": "ITI-007", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Dementia,", 
            "Healthy", 
            "geriatric", 
            "volunteers", 
            "patients"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Glendale", 
                    "country": "United States", 
                    "state": "California"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, Multiple Oral Dose Escalation for Safety, Tolerability and Pharmacokinetics of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia.", 
        "other_outcome": [
            {
                "measure": "Exploratory measures of cognitive function", 
                "safety_issue": "No", 
                "time_frame": "Baseline and up to 7 days"
            }, 
            {
                "measure": "Exploratory measures of agitation", 
                "safety_issue": "No", 
                "time_frame": "Baseline and up to 7 days"
            }, 
            {
                "measure": "Exploratory measures of subjective sleep", 
                "safety_issue": "No", 
                "time_frame": "Baseline and up to 7 days"
            }
        ], 
        "overall_contact": {
            "email": "kvanover@intracellulartherapies.com", 
            "last_name": "Kimberly Vanover, Ph.D.", 
            "phone": "+1-212-923-3344"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Vital signs, 12-lead ECGs, clinical laboratory testing, and adverse events will be assessed.", 
            "measure": "Number of participants with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "up to 7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02078310"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Area under the concentration-time curve (AUC)", 
            "safety_issue": "No", 
            "time_frame": "pre-dose and multiple collection points up to 72 h after the last dose"
        }, 
        "source": "Intra-Cellular Therapies, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Intra-Cellular Therapies, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}